Why the study?
This study aimed to explore the clinical characteristics of patients with type 2 diabetes and COVID-19, and determine the impact of type 2 diabetes on clinical outcomes.
Does type 2 diabetes worsen clinical outcomes and increase mortality in hospitalized patients with COVID-19?
Observational (n=4,559)
No
Does type 2 diabetes worsen clinical outcomes and increase mortality in hospitalized patients with COVID-19?
Type 2 diabetes, particularly when newly diagnosed or accompanied by coronary artery disease or chronic kidney disease, is associated with significantly higher mortality and disease severity in patients hospitalized with COVID-19.
Answers are grounded in this paper and cite their sources.
New-onset T2D may heighten mortality vigilance in COVID-19 inpatients; leaves open causal confirmation and targeted interventions.
Background and Objectives: Diabetes mellitus is associated with poor clinical outcomes in patients with coronavirus disease 2019 (COVID-19). This study aimed to explore the clinical characteristics of patients with type 2 diabetes with COVID-19, and to determine the impact of type 2 diabetes on clinical outcome of patients with COVID-19. Material and Methods: This single-center, retrospective, observational study enrolled patients admitted from March 2020 to June 2021 with COVID-19. The clinical and biochemical characteristics of patients with known type 2 diabetes, newly diagnosed diabetes, type 2 diabetes with comorbidities and those who succumbed to illness were analyzed. Results: Of 4,559 patients with COVID-19, 2,090 (45.8%) had type 2 diabetes. Patients with COVID-19 with diabetes were older, more likely to receive mechanical ventilation, had higher odds of mortality from COVID-19 as compared with patients without diabetes. In addition, patients with diabetes had significantly higher levels of serum creatinine, C-reactive protein, ferritin, lactate dehydrogenase, and D-dimer. Compared with previously diagnosed patients with diabetes, newly diagnosed patients had higher mortality (33% vs. 27%, P = 0.049). Among patients with COVID-19 and diabetes, nonsurvivors had significantly higher levels of inflammatory markers and had severe impairment of cardiac, renal, and coagulation parameters as opposed to survivors. Conclusion: Patients with COVID-19 with diabetes were more likely to have severe disease and had higher mortality. Presence of chronic kidney disease and coronary artery disease in patients with diabetes with COVID-19 was associated with adverse outcome. Patients with newly diagnosed diabetes had higher odds of severe disease at presentation and had higher mortality.
No takes yet. Share an insight, caveat, or question.
Mittal et al. (2022) conducted an observational in COVID-19 (n=4,559). Type 2 diabetes vs. No diabetes was evaluated on mortality (newly diagnosed vs previously diagnosed diabetes) (p=0.049).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: